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Background: Cutaneous leishmaniasis (CL) is an endemic disease in Iraq, for which many therapies had been tried, aiming to induce
cure with no or minimal scaring. Rifamycin is an antibacterial agent, with the ability to inhibit bacterial DNA-dependent RNA synthesis
and it is eﬀective against extra- and intracellular microorganisms. Objective: To evaluate the eﬀectiveness and safety of intralesional
8.33% Rifamycin inﬁltration in treatment of cutaneous leishmaniasis. Patients and methods: This is an open controlled therapeutic trial,
carried out in the outpatient clinic of Dermatology & Venereology, Al-Yarmouk Teaching Hospital during the period between the ﬁrst of
December 2013 to the end of June 2014. A total of 29 patients have been enrolled in this therapeutic trial, however 4 patients were
defaulted and 25 patients have completed the therapeutic trial. Fourteen (56%) were males and 11 (44%) were females, with a male
to female ratio 1.27. Their ages ranged from 6 to 60 years, with a mean ± SD of 28.6 ± 14.9 years. The total number of lesions was
56 and the duration of lesions ranged between 4 and 18 weeks with a mean ± SD of 9.9 ± 4.4 weeks. The size of lesions ranged from
0.5 to 6 cm in diameter with a mean ± SD of 2.46 ± 1.17 cm. All patients have been diagnosed through history and clinical examination
and the diagnosis was conﬁrmed by skin smear and biopsy. The lesions were divided into two groups; group A treated with intralesional
8.33% Rifamycin inﬁltration every 2 weeks for a maximum of 5 sessions, while group B was left untreated as a control group. Follow up
was every 2 weeks during the treatment period, and for 6 weeks after completing the therapeutic sessions. Results: Twenty ﬁve patients
with a total of 56 lesions were completed the study period. Twenty one (37%) lesions were ulcerative and 35 (63%) were non ulcerative
lesions. Ten (40%) patients had single lesion whereas 15 (60%) patients had multiple lesions. In group A, 38 (92.7%) out of 41 lesions
showed a cure with 2–5 sessions with a mean ± SD of 4.9 ± 0.79 sessions, while in the control group no lesion had signiﬁcantly improved
or cured. At the end of the study period, only 8 out of 41 treated lesions have left trivial scars. Most of the lesions showed transient
hyperpigmentation at the end of the study, but fortunately, it had disappeared in all cases few weeks later. Conclusion: Rifamycin
8.33% solution given intralesionally in cutaneous leishmaniasis is a highly eﬀective agent with a success rate of 92.7%. For cure, it needs
2–5 local inﬁltrations given every two weeks. In addition to being eﬀective, it is a safe, and less costly therapeutic option for cutaneous
leishmaniasis.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cutaneous leishmaniasis (CL) is a zoonotic disease
caused by infestation with a protozoan of the genus Leish-
mania. The disease is endemic in Iraq and other
Middle East countries (Desjeux, 1992; Neouimine, 1996).ehalf of King Saud University.
commons.org/licenses/by-nc-nd/4.0/).
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bite of infected female sand ﬂy species of Lutzomyia and
Phlebotomus (Levin et al., 1980). Although CL is a self
healing disease, spontaneous cure may take several months
or even years (Sharquie et al., 2001; Sharquie and Al-Talib,
1988), but invariably leaving the patient permanently
scared, a stigma which can cause serious social prejudice
(Sharquie and Al-Talib, 1988). An estimated 2 million
new cases (1.5 million cases of cutaneous leishmaniasis
and 500,000 of visceral leishmaniasis) occur annually, with
about 12 million people currently infected (Magnitude of
the problem, 2011). Over 90% of CL cases occur in Afgha-
nistan, Algeria, Iran, Iraq, Saudi Arabia, Syria, Brazil and
Peru (Desjeux, 2004). CL is caused by Leishmania which is
a ﬂagellated protozoan of phylum Sarcomastigophora. The
vector host of CL is mosquitoes of the genus Phlebotomus,
of various species like; P. papatasi, P. sergenti, and
P. macedonicum (Faust, 1975; Vegas Francisco, 1976;
Sarhan, 1985). Clinically the disease can be seen as dry
and wet type (Ghosn and Kurban, 2008). The incubation
period is relatively short (1–4 weeks) for wet type and
longer (2–8 months or more) for dry type. The rash appears
as a macule that rapidly becomes a painless, non-itchy
papule which is dusky red in color. With time it might
enlarge to become a nodule or a plaque. This stage is called
dry (non ulcerative) type leishmaniasis. The lesion may
become crusted at the center and then ulcerate forming
the wet (ulcerative) type of leishmaniasis (Griﬃths and
Croft, 1980). Other forms of the disease are diﬀuse
cutaneous leishmaniasis, leishmania recidivans, lupoid
leishmaniasis and post kala-azar dermal leishmaniasis.
Although CL is a self-limiting disease, it is disﬁguring,
therefore, the main objectives of treatment of CL are:
shortening the duration of the disease, improving the cos-
metic results of its scar and to cut short psychological
impact on the patients (Sharquie and Al-Talib, 1988).
There are diﬀerent ways of treating CL that may include:
1. Local treatment: like; heat therapy (Selim et al., 1990),
cryotherapy (Gurei et al., 2000), laser (Shamsi
Meymandi et al., 2011), local inﬁltration with sodium
stibogluconate (Sharquie and Al-Talib, 1988), hyper-
tonic sodium chloride (Sharquie et al., 1994), chloro-
quine (Yasmin et al., 2011), zinc sulfate solution
(Sharquie et al., 1997) and topical application of paro-
momycin (Asilian et al., 2003) and azole agents (Larbi
et al., 1995).
2. Systemic treatments: like; pentavalent antimonials (Joint
Formula Committee, 2014), antifungal drugs
(Salmanpour et al., 2001; Momeni et al., 1996; Ghosn
and Kurban, 2008), rifampicin, (Jaﬀar, 2006) Azithro-
mycin, (Silva-Vergara et al., 2004) Dapsone, (Al-
Mutaii et al., 2009) and Immunomodulating agents like
oral zinc sulfate (Sharquie et al., 2001) and interferon
c (Khatami et al., 2007). These therapeutic options have
been associated with diﬀerent success rates and may
have certain side eﬀects during or after treatment.2. Patient and methods
This is an open controlled therapeutic trial, carried out
in the outpatient clinic of Dermatology & Venereology,
Al-Yarmouk Teaching Hospital, Baghdad during the per-
iod between the 1st of December, 2013 to the end of June,
2014. A full history was taken from each patient regarding
age, sex, occupation, residence, duration of the lesions,
family history of similar lesions, history of pregnancy,
and history of any previous therapy.
Thorough physical examination was performed
regarding the number, site, size, consistency and type
of the lesions (ulcerative and non-ulcerative lesions).
Regional lymphadenopathy was also checked for during
examination.
All patients diagnosed with CL during the study period
were included in this work except patients with the follow-
ing criteria:
 Patients received any anti–leishmanial treatment for at
least one month before this study.
 Patients with liver disease.
 Patients with lesions close to the eyes or lesions involv-
ing the nose or ears.
 Patients with history of hypersensitivity to Rifamycin
group of drugs.
 Patients with large-sized lesions (larger than 6 cm in
diameter).
 Patients with large number of lesions (more than 5
lesions).
 Pregnant women.
The ethical approval was given by the Scientiﬁc Com-
mittee of the Scientiﬁc Council of Dermatology and
Venereology, Iraqi Board for Medical Specializations. All
patients have been informed and fully-explained about
the nature of disease and the therapy that will be used
and a formal consent was taken from each patient. The
diagnosis of every case was made on a clinical background
and conﬁrmed by skin smear and biopsy.
The lesions have been divided into two groups:
Group A: Lesions were treated with a local inﬁltration
(intralesional) of 8.33% Rifamycin solution which was
obtained in a form of readymade medication, 250 mg/3 ml
ampoule. It was purchased from FARMA KOCAK Phar-
maceutical and Chemical Industry, Turkey. It is injected
intradermally using (26 gauge insulin needle) at an angle
45 to the lesion surface, with the injected amount at a rate
of 0.5 ml per cm2). One intralesional session of Rifamycin
was given every two weeks for a maximum of ﬁve total
sessions.
Group B: Lesions in this group have received no treat-
ment and left as a control (an average of one control lesion
for each patient with two or more lesions).
All lesions were assessed for the degree of erythema, the
size, and palpated to assess the degree of induration. How-
ever the main parameter of assessment was reduction in the
Table 1
The number of lesions in patients with cutaneous leishmaniasis.
Number of lesions Number of patients Percentage (%)
Single 10 40
2 4 16
3 7 28
4 3 12
5 1 4
Total = 56 Total = 25 100
Table 2
The frequency distribution of lesions according to the site of involvement.
Site Number of lesions Percentage (%)
Upper extremities 48 85.7
Lower extremities 5 8.9
Trunk 2 3.6
Face 1 1.8
Neck 0 0
Total 56 100
Table 3
The score of response in all treated lesions of cutaneous leishmaniasis.
Grade of
response
Number of
lesions
Percentage
(%)
Number of
sessions
Slight 0 0 0
Mild 0 0 0
Moderate 3 7.3 5 sessions
Marked 1 2.5 5 sessions
Total clearance 37 90.2 2–4 sessions
No response 0 0 0
Total 41 100
Mean ± SD sessions = 4.9 ± 0.79.
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ing) system Sharquie and Al-Talib, 1988:
 Slight: decrease in erythema and indurations of the
lesion.
 Mild: reduction in the size of the lesion up to 30%.
 Moderate: reduction in the size of the lesion of 30–60%.
 Marked: reduction in the size of the lesion >60%.
 Total clearance of the lesion.
2.1. Both marked improvement and total clearance were
considered as a clinical cure (Sharquie and Al-Talib, 1988)
The size of each lesion was measured using ﬁnely cali-
brated tape measure in centimeter unit. For rounded
lesions one diameter was taken, whereas for irregularly-
shaped lesions, the two maximum diameters (length and
width) were taken to calculate the mean. In each visit
(every 2 weeks) the diameter of lesions were measured in
addition to assessing the degree of erythema and indura-
tion, and compared with the results of previous visits to
assess the degree of improvement or resolution. Photos
were taken in a standardized way according to place, light
exposure, and distance using Canon Power Shot SX260HS
camera 12.1 Megapixel.
Patients were assessed every 2 weeks and at each visit
the scoring was re-assessed to estimate the degree of the
response and record any local and systemic side eﬀects.
All patients were followed-up for further 6 weeks after
completing their therapeutic sessions for further assessment
of therapeutic results obtained and the fate of side eﬀects if
any.
SPSS program (version 21) was used for descriptive
(number, mean, percentage, range and standard deviation)
and analytic statistics using Chi-squire (v2) and P value for
data analyses.
3. Results
A total of 29 patients have been enrolled in this thera-
peutic trial, however 4 patients with a total of 6 lesions
were defaulted and 25 patients with a total of 56 lesions
were completed the study period. Fourteen (56%) were
males and 11 (44%) were females, with a male to female
ratio 1.27. The age ranged from 6 to 60 years, with a
mean ± SD of 28.6 ± 14.9 years. The youngest patient
was 6 years old and the oldest patient was 60 years old.
The total numbers of lesions were 56 lesions, with 21
(37.5%) ulcerative lesions and 35 (63.5%) non ulcerative
lesions. The duration of the lesions was 4–18 week with a
mean ± SD of 9.9 ± 4.4 weeks. The size of lesions ranged
from 0.5 to 6 cm in diameter with a mean ± SD of 2.46
± 1.17 cm. Ten (40%) patients had single lesion whereas
15(60%) patients had multiple lesions (Table 1).
The most common site aﬀected by cutaneous leishmani-
asis was the upper extremities 48 (85.7%), then the lowerextremities 5 (8.9%), while the least aﬀected site was the
face (1.8%) (Table 2).
Group A, Forty one lesions were treated, 38 (92.7%)
lesions showed a cure, of which, 37 (90.2%) lesions showed
total clearance of the lesions and one (2.5%) lesion had
marked improvement. The number of sessions ranged from
2 to 5 with a mean ± SD of 4.9 ± 0.79 sessions. The
remaining 3 (7.3%) lesions showed moderate response with
5 sessions (Table 3). Thirty seven (90.2%) lesions had com-
plete clearance with 2–4 sessions, mean ± SD of 3.83
± 0.72 sessions, where 13 lesions totally cleared with only
2 sessions, 17 lesions by 3 and 7 lesions by 4 sessions
(Figs. 1–3).
This study has revealed that non ulcerative lesions were
better responsive than ulcerative ones, as all 26 (100%) non
ulcerative lesions versus 12 out of 15 (80%) ulcerative
lesions were cured. This was statistically signiﬁcant (P
value = 0.017).
Group B, The 15 control lesions showed no sign of
improvement after completing the study period except for
2 (13.3%) lesions which showed slight clinical
improvement.
A B
Figure 1. A 19-year-old female with CL. (A) Before treatment, (B) After two sessions of intralesional Rifamycin injection.
A B
Figure 2. A 34-year-old female with CL. (A) Before treatment, (B) After two sessions of intralesional Rifamycin injection (Complete clearance).
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eﬀects from using Rifamycin solution intralesionally, how-
ever, regarding local side eﬀects, mild pain at the inﬁltra-
tion site was encountered in 18 (72%) patients and
moderate pain in 7 (28%) patients. At the end of the study
only 8 (19.5%) out of 41 treated lesions have left scarring, it
was slight in all cases, as none of them exceeded the size of
the one third of the original lesion. Postinﬂammatory
hyperpigmentation was seen in most of the treated lesions,
however, it was transient and took just few weeks to
disappear.
4. Discussion
CL is a self-healing disease; however spontaneous cure
may take several months or even years. Many therapeutic
agents were used to shorten the duration of lesions and
to prevent or minimize scarring (Sharquie and Al-Talib,
1988).Regarding age groups aﬀected by CL, the present work
has shown that adult were more commonly involved than
children (75% versus 25%), this may diﬀer from the ﬁnding
of many previous studies that had shown predominance of
children involvement (Vegas Francisco, 1976; Sharquie
et al., 1997; Layegh et al., 2013). However, adult more than
children involvement by CL have been reported (Armijos
et al., 1997). The mean age group was 28.6 ± 14.9 and this
goes in parallel with many other published studies
(Sharquie and Al-Talib, 1988; Yasmin et al., 2011; Al-
Zoubaidi, 2012; Hamdi et al., 2010). Males were more
aﬀected than females in the present study with a male to
female ratio 1.27. This was similarly reported by many pre-
vious studies (Yasmin et al., 2011; Armijos et al., 1997;
Hamdi et al., 2010; Velez et al., 2001).
Regarding the type of CL lesions, 26 (about 63%) lesions
were non ulcerative versus 15 (about 37%) lesions were
ulcerative. The clinical types of lesions of CL whether
ulcerative or none ulcerative usually depend on the clinical
A B
Figure 3. A 30-year-old male with CL. (A) Before treatment, (B) After 4 sessions of intralesional Rifamycin injection.
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tive CL, which in turn is mainly a reﬂection of the type of
species of the causative Leishmania protozoa that diﬀer in
their pathogenicities. This study was not concerned with
the clinical types of lesions regarding wet and dry varieties,
but rather ulcerative and non-ulcerative lesions to detect
any diﬀerence in their responsiveness to the assessed thera-
peutic agent. However the predominance of non-ulcerative
lesions may be partly explained by the relatively early pre-
sentation of the patients enrolled in this study, as the dura-
tion of the lesions ranged from 4 to 18 weeks with a mean
of 10 weeks and it is well documented that ulceration may
start after 3 months of the onset of infection and it may be
delayed to many month later in dry type (Ghosn and
Kurban, 2008).
Regarding the site of involvement by cutaneous leishma-
niasis in the present study, most of the lesions were on the
exposed parts of the body and in order of decreasing fre-
quency these were; the upper extremities (85.7%), the lower
extremities (8.9%), whereas only 3.6% were on the trunk.
This is expected as CL is an insect-born infestation and it
goes in parallel with the published literature regarding
the predominance of exposed parts involvement by CL
(Ghosn and Kurban, 2008; Sharquie et al., 1994, 1997).
However, face involvement was rare in this study and this
may be secondary to the exclusion criteria applied in which
lesions around oriﬁces like nose, eyes, and ears were
excluded.
A lot of therapeutic options for CL are available, how-
ever local chemical inﬁltrations may be considered as an
appropriate method of treatment, especially for small,
non-inﬂamed lesions that are not at risk to progress to
mucocutaneous leishmaniasis (Ghosn and Kurban, 2008).
Also intralesional injection of leishmaniasis sore is a tradi-
tional method of treatment recommended by the WorldHealth Organization in endemic areas (Hamdi et al.,
2010; Dawlati, 1996; Ahmed, 1982).
Many therapeutic agents given intralesionally have been
tested previously with diﬀerent success rates, like; Sodium
stibogluconate, (Sharquie and Al-Talib, 1988) Meglumin
antimoniate, (Chehade and Douba, 1990) Hypertonic
sodium chloride solution (7%), Sharquie et al., 1994 Zinc
sulfate solution (2%), Sharquie et al., 1997 Metronidazole,
(Sharquie et al., 2004) ]Bleomycin (1%), Soyuer and Aktas,
1988 Ciproﬂoxacin (0.2%) Hamdi et al., 2010 and
Chloroquine. (Yasmin et al., 2011).
We have tried Rifamycin, which is for our best knowl-
edge, has not been tried before for CL through intrale-
sional inﬁltration. Rifamycin is an antibacterial drug and
it is related to Rifampicin (both are belonging to Rifamycin
group), its activity relies on the inhibition of bacterial
DNA dependent RNA synthesis and it is eﬀective against
intra and extracellular located microorganism (Feklistov
et al., 2008; Campbell et al., 2001).
We have found a ﬁnal success rate of 92.7% among
patients with CL involved in this study with intralesional
Rifamycin inﬁltration versus none of the controlled lesions.
This success rate can be considered very comparable with
the success rates of many eﬀective intralesional chemical
therapeutic agents previously studied like; Sodium sti-
bogluconate antimony (94.6%) Sharquie and Al-Talib,
1988, Meglumine antimoniate (100%) Chehade and
Douba, 1990; Yasmin et al., 2011, Hypertonic sodium
chloride solution 7% (96%) Sharquie, 1995, Zinc sulfate
solution 2% (94.8) Sharquie et al., 1997, Metronidazole
0.5% and 5% (with success rates of 85% and 87% respec-
tively) (Sharquie et al., 2004), Chloroquine (100%)
Yasmin et al., 2011, Bleomycin (100%) Soyuer and
Aktas, 1988 and Ciproﬂoxacin 0.2% (81.5%) Hamdi
et al., 2010.
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ged from 2 to 5 sessions given at 2 weeks interval, which
was comparable with many other agents like; Ciproﬂoxa-
cin, Metronidazole (0.5% and 5%) and Hypertonic sodium
chloride solution (7%) (Hamdi et al., 2010; Sharquie et al.,
2004; Sharquie, 1995). However, the number of required
therapeutic sessions in this study was less than the average
number of injections needed with Meglumin antimoniate
and Chloroquine (Yasmin et al., 2011). Still the number
of sessions needed with Sodium stibogluconate (Sharquie
and Al-Talib, 1988) was less than with Rifamycin injection
used in this study.
Rifamycin intralesionally in addition to be eﬀective, it is
associated with insigniﬁcant side eﬀects as only 8 out of 41
lesions ended with a scar, which is minimal in all cases and
this coincides with many other successful therapeutic
agents (Yasmin et al., 2011; Sharquie et al., 1997, 2004;
Sharquie, 1995; Hamdi et al., 2010; Soyuer and Aktas,
1988).
Most of the treated lesions (38 out of 41 lesions) with
Rifamycin inﬁltration have left transient localized hyper-
pigmentation which was subsided after few weeks in all
cases. Many other therapeutic agents used intralesionally
in CL lesions have left similar hyperpigmentation which
was transient (Yasmin et al., 2011; Sharquie et al., 1997,
2004; Sharquie, 1995).
Comparing the results which have been obtained with
intralesional Rifamycin used in the present work with oral
Rifampicin, we have found that intralesional Rifamycin
was superior to oral Rifampicin in success rate (92.7%) ver-
sus (61.8%) Jaﬀar (2006) and (73.9%) Kochar et al. (2000)
with nearly similar duration of treatment. However the
dose of Rifampicin used was too high (1200 mg/day)
(Kochar et al., 2000), which may necessitate serological
and biochemical assessment regarding complete blood
count, liver and renal function tests before, during and
after treatment (Jaﬀar, 2006).
5. Conclusion
Rifamycin 8.33% solution given intralesionally in cuta-
neous leishmaniasis is a highly eﬀective agent with a success
rate of 92.7%. For cure, it needs 2-5 local inﬁltrations given
every two weeks. In addition to being eﬀective, it is a
safe and less costly therapeutic option for cutaneous
leishmaniasis.
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